Glp1-Dual-Agonist on Bioeconhttps://en.bioecon.ru/technologies/glp1-dual-agonist/Recent content in Glp1-Dual-Agonist on BioeconHugoen-USSun, 05 Jul 2026 16:59:21 +0700Drug & vaccine developmenthttps://en.bioecon.ru/technology/drug-vaccine-development/Sun, 05 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/drug-vaccine-development/The end-to-end R&D pipeline that carries a drug or vaccine candidate from target identification through Phase I-IV clinical trials to regulatory approval — a 7-15-year, billion-dollar process now being reshaped by personalized mRNA platforms, GLP-1 blockbuster economics and competing FDA, EMA and NMPA regulatory-acceleration reforms.